156 results about "Estradiols" patented technology

The invention provides a nucleic acid aptamer for specific recognition of morphine and application of the nucleic acid aptamer, and belongs to the technical field of biosensing and detection. The nucleotide sequence of the nucleic acid aptamer is as shown in SEQ ID NO: 1. The screening method is based on a Capture-SELEX technology and comprises the key steps that streptavidin magnetic beads are used for fixing an ssDNA library, estradiol, deabietic acid and totarol are introduced to serve as reverse screening substances so as to remove non-specific sequences, and finally the high-specificity aptamer is obtained through high-throughput sequencing and affinity determination. The dissociation constant of the aptamer and morphine is 127.31 nM, and the aptamer shows high affinity and high specificity. The invention further relates to application of the aptamer in preparation of a sensor and a kit for detecting morphine, and a new technical means is provided for rapid detection of morphine.

Provided are methods for determining the amount of estradiol in a sample using mass spectrometry. The methods generally involve ionizing estradiol in a sample and detecting and quantifying the amount of the ion to determine the amount of estradiol in the sample.

The present invention relates to an oral extract composition comprising Shatavari (Asparagus racemosus Willd.) and Fenugreek (Trigonella foenum-graecum L.) extract composition, and its process of preparation. Also relates to the oral extract composition formulation comprising with synergistic combinations of the Shatavari (Asparagus racemosus Willd.) and Fenugreek (Trigonella foenum-graecum L.) in suitable doses and at least one nutraceutically and / or pharmaceutically accepted excipient for, improvement, and maintenance of women health more preferably in improving of hot flashes, night sweats, poor sleep, anxiety, sexual dysfunction, mood changes, Genitourinary symptoms in overall improving the quality of life, serum estradiol, progesterone, follicle stimulating hormone (FSH), and cortisol during the period of menopause (perimenopause and menopause). The oral extract composition formulation comprising with synergistic combinations of the Shatavari (Asparagus racemosus Willd.) and Fenugreek (Trigonella foenum-graecum L.) in suitable doses and at least one nutraceutically and / or pharmaceutically accepted excipient is used for improving Brain-derived neurotrophic factor (BDNF) levels in women during the period of menopause. The present invention, further related to the extraction process of Shatavari (Asparagus racemosus Willd.) and Fenugreek (Trigonella foenum-graecum L.), also provides the process for the preparation of formulation composition. This invention further relates to the extraction process from Shatavari (Asparagus racemosus Willd.) and Fenugreek (Trigonella foenum-graecum L.) either as individual herbs or co-extraction of the two herbs or mixing the extracts at various stages of the individual extracts.

The invention discloses an aptamer electrochemical biosensor for estradiol detection as well as a preparation method and application of the aptamer electrochemical biosensor. The aptamer electrochemical biosensor is obtained by growing AuNPs particles on the surface of MoS2 to prepare a MoS2-AuNPs composite material, fixing the composite material on the surface of an electrode through chitosan, hybridizing aptamer probes P1 and P2, and self-assembling the aptamer probes P1 and P2 on the surface of the electrode through Au-S bonds. The sensor can be used for in-situ detection of hormone factor estradiol in sweat, can be applied to non-invasive monitoring equipment, and provides reliable and timely monitoring data.

The invention discloses bifidobacterium adolescentis for relieving estrogen-related metabolic disorder and obesity and application thereof, and belongs to the technical field of microorganisms. The bifidobacterium adolescentis CCFM1506 screened by the invention can effectively improve ovariectomized individual estrogen disorder symptoms, obviously slow down the weight increase speed and weight increment of estrogen disorder individuals, increase the expression quantity of serum estradiol, CYP11A1 and ERalpha in adrenal gland and the high-density lipoprotein content in serum, reduce the total cholesterol and glucose level and improve the ovariectomized ovariectomized ovariectomized ovariectomized ovariectomized ovariectomized ovariectomized ovariectomized ovariectomized abnormal glucose and lipid metabolism is adjusted; the invention has the advantages of simple preparation method and wide application prospect, can be used for preparing medicines for relieving or treating estrogen-related metabolic disorders and obesity, and can be used for preparing health-care products beneficial to controlling in-vivo fat and maintaining the health level of blood fat, and has obvious physiological effects and wide application prospects, and can be used for preparing the medicines for relieving or treating the estrogen-related metabolic disorders and obesity and preparing health-care products beneficial to controlling in-vivo fat and maintaining the health level of blood fat. A new thought and a new basis are provided for developing functional foods or medicines based on the probiotics.

Provided are methods of contraception using as a first line combined oral contraceptive (COC), a COC composition comprising nomegestrol acetate (NOMAC) and estradiol or an ester thereof. Said COC compositions are associated with a lower risk of venous thromboembolism (VTE) as compared to other CHCs. The compositions may also be used in methods of treatment in women having conditions linked to menstruation and / or fertility.

This invention discloses a method for large-scale breeding of all-male salmon and trout, belonging to the field of fish sex regulation breeding technology. The method includes: collecting fertilized eggs from different families of the same species of salmon and trout, artificially incubating them to obtain fry, and inducing sex reversal in the fry by using 17β-estradiol when they begin feeding; subsequently, raising the fry to sexual maturity, selecting individuals with a female phenotype, and then using sdY as a sex identification gene, selecting pseudo-females with genotype XY by quantitative real-time PCR; pairing the sexually mature pseudo-females with genotype XY with normal males with genotype XY, and obtaining super-males with genotype YY through artificial insemination; pairing the sexually mature super-males with females with genotype XX, and producing all-male salmon and trout with genotype XY on a large scale through artificial insemination. This invention overcomes the problem that existing technologies cannot achieve large-scale breeding of all-male salmon and trout.

This invention belongs to the field of analytical detection technology and relates to a method for detecting estradiol using a combination of organometallic framework enrichment and enzyme-linked immunosorbent assay (ELISA). A magnetic organometallic framework solid-phase extractant is used to enrich estradiol in the sample, followed by detection of the enriched estradiol using ELISA. The magnetic organometallic framework solid-phase extractant is prepared by subjecting mercaptoacetic acid-modified Fe3O4 particles, zirconium salt, and 2-amino-terephthalic acid to a solvothermal reaction at 110–130°C for 22–26 hours. The detection method provided by this invention has advantages such as short detection time, high sensitivity, good specificity, and high accuracy, thereby enabling the detection of trace amounts of estradiol in environmental water samples.

This invention discloses an in vitro maturation culture medium for ferret oocytes and its preparation method, belonging to the field of animal embryo engineering technology. It comprises the following components: TCM199 basal culture medium, 50 mL fetal bovine serum, 25 IU follicle-stimulating hormone, 25 IU luteinizing hormone, 0.5 mg 17β-estradiol, 0.005 mg epidermal growth factor, 12.1 mg sodium pyruvate, 0.2 mM cysteine, 0.1 mM cysteine, 0.030 g penicillin, 0.025 g streptomycin sulfate, as well as an antioxidant complex, a combination of growth factors, and extracellular matrix components. This invention provides a comprehensive and suitable nutritional environment for ferret oocytes by precisely formulating a composite culture medium containing multiple key components. Specifically, the hormone combination at specific concentrations accurately simulates the in vivo physiological environment, effectively regulating the oocyte maturation process; multiple growth factors work synergistically to promote oocyte growth, development, and differentiation; and the addition of the antioxidant complex effectively eliminates free radicals generated during in vitro culture, reducing oxidative stress damage to oocytes.

The invention belongs to the technical field of transdermal patches, and relates to a transdermal patch for improving the bioavailability of estradiol and a preparation method of the transdermal patch. The transdermal patch is prepared from the following components in percentage by weight: 5 to 21 percent of estradiol, 8 to 15 percent of polymer matrix, 0.5 to 1.5 percent of butylated hydroxytoluene, 10 to 15 percent of hydrogenated rosin glyceride, 2 to 5 percent of penetration enhancer, 3 to 8 percent of plasticizer and 25 to 35 percent of solvent. According to the transdermal patch disclosed by the invention, continuous and stable release of a medicine is realized, the transdermal absorption rate of estradiol is improved, so that the bioavailability is improved, the treatment effect is further improved, and meanwhile, the transdermal patch disclosed by the invention can also avoid a first-pass effect of the liver and reduce side effects; the transdermal drug delivery system is convenient to use, and the compliance of a patient is improved.

The application provides an application of a traditional Chinese medicine preparation in preparation of a drug for treating dysmenorrhea, and an active ingredient of the traditional Chinese medicine preparation is prepared from liquorice, asarum, cassia twig, angelica, white peony root, common sage and chuanxiong. The traditional Chinese medicine preparation provided by the application fuses multi-dimensional treatment strategies of warming meridians, nourishing blood, regulating qi and dredging collaterals, and can cover different TCM syndrome types such as cold coagulation and blood stasis, qi stagnation and blood stasis and qi and blood deficiency. Pharmacological experiments show that for dysmenorrhea rats of the cold coagulation and blood stasis type, the traditional Chinese medicine preparation of the application can reduce the sensitivity of the uterus caused by benzoic acid estradiol and inhibit the writhing reaction of the rats caused by oxytocin, which indicates that the traditional Chinese medicine preparation of the application has the effect of treating dysmenorrhea.

Among hospital–acquired infections, Pseudomonas aeruginosa-associated urinary tract infections (UTIs) are mainly caused by indwelling urethral catheters (catheter-associated UTIs or CAUTIs) and are difficult to treat, resulting in high rates of morbidity among hospitalized patients. While antibiotics can successfully treat bacteria in the bladder lumen, they are inefficient at crossing stratified urothelium plasma membranes to kill persistent intracellular bacterial communities (IBCs). Herein, UTI IBCs are targeted by locally delivering the antibiotic gentamicin and / or the steroid hormone estradiol via polymeric nanogels conjugated with a cell-penetrating peptide Cys-Gly-Lys-Arg-Lys (CGKRK - SEQ ID NO:1). This approach delivered more intracellular gentamicin compared to drug delivered in solution in vitro and more estradiol compared to conventional methods. In an acute UTI murine model, the nanogel cell-penetrating peptide drug delivery system facilitated the transport of gentamicin into the urothelium and resulted in > 90% clearance of a uropathogenic P. aeruginosa clinical strain in vivo.

The application relates to the field of biotechnology, and particularly relates to an application of Bacteroides ovatus in ovarian aging; the application comprises: taking low-abundance Bacteroides ovatus as a biomarker of ovarian aging; the application comprises using Bacteroides ovatus in a medicine for delaying ovarian aging; the application further comprises using a fermentation product of Bacteroides ovatus in the medicine for delaying ovarian aging; it is found through experiments that there is a significant difference in Bacteroides ovatus in mice with different degrees of ovarian aging, and it is found through subsequent experiments that Bacteroides ovatus has the effects of significantly increasing the number of oocytes, up-regulating anti-Mullerian hormone, up-regulating the level of estradiol and down-regulating the level of follicle-stimulating hormone, which indicates that Bacteroides ovatus can be used in the medicine for delaying ovarian aging.

The invention belongs to the technical field of biomedical materials, and particularly relates to a temperature-sensitive estradiol hydrogel composition, a preparation method and application. According to the composition, a temperature-sensitive responsive network is constructed by introducing a PCL-PEG-PCL triblock copolymer, modified chitosan, a penetration enhancer and a buffer regulation system, so that rapid gelling, controlled-release drug delivery and good retention under a body temperature condition are realized. Through systematic contrast experiments with a plurality of contrast samples, evaluation is carried out from four aspects of gelling performance, drug release behavior, degradation residual rate and adhesiveness, and results show that the composition in a preferable ratio has the comprehensive advantages of good gel stability, long drug release period, good biodegradability, lasting uterine cavity adhesion and the like; good post-operation anti-adhesion and local drug delivery application prospects are realized.

The invention relates to a new modified release oral pharmaceutical form comprising 17α-cyanomethyl-17-β-hydroxyestra-4,9-dien-3-one (dienogest) and 17α-ethinylestradiol (ethynyl estradiol), its method of production and its medical and non-medical uses, in particular its use in contraception.

The invention discloses a premature delivery risk assessment method based on abundance of estradiol degradation genes in excrement samples in the early pregnancy stage, and the method is used for assessing the premature delivery risk of a maternal body based on abundance information of novel estradiol degradation genes in the excrement samples of individuals in the early pregnancy stage. The specific gene is k1412944177, and the nucleotide sequence of the specific gene is SEQ. NO. 1. Research finds that the gene can be used as a biomarker for evaluating the premature delivery risk at the early pregnancy stage, and by detecting the relative abundance of the gene in a maternal excrement sample at the early pregnancy stage, a scientific and accurate risk evaluation basis can be provided for the maternal premature delivery risk. And the expression of the biomarker also has the capability of degrading and regulating estradiol related to premature delivery, so that a brand new thought is provided for precise prevention of premature delivery and individualized obstetrical management.

The present application belongs to the field of biomedicine, and relates to an inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells. The inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells is based on a human mesenchymal stem cell serum-free culture medium, and is composed of the following components in a mass concentration ratio: bone morphogenetic protein-4 20-60 mg / L, bone morphogenetic protein-7 20-60 mg / L, tretinoin 2-8 mg / L, resveratrol 2-8 mg / L, icariin 2-8 mg / L, benzamide 2-8 ug / L, chloroplatinic acid hexahydrate 2-8 ug / L, ethanolamine 2-8 ug / L, erythropoietin 2-10 ug / L, and vascular endothelial growth factor 2-10 ug / L. The inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells has high induction efficiency.

Disclosed herein is, among other things, a soft gel vaginal pharmaceutical composition and dosage form containing solubilized estradiol for the treatment of vulvovaginal atrophy (VVA) and female sexual dysfunction (FSD).

This invention belongs to the field of biomedicine and discloses estradiol derivatives or pharmaceutically acceptable salts thereof with the structure shown in Formula I: R is selected from R1, which is selected from F, Cl, Br, and I; L is selected from straight-chain or branched alkyl groups with 2 to 10 carbon atoms. This invention also discloses the use of the estradiol derivatives or pharmaceutically acceptable salts thereof in the preparation of drugs for treating depression and anxiety. Furthermore, this invention discloses the use of the estradiol derivatives or pharmaceutically acceptable salts thereof in the preparation of drugs targeting ERβ / SERT for treating depression and anxiety. The estradiol derivatives of this invention can simultaneously and effectively inhibit SERT and activate ERβ, thereby synergistically enhancing serotonergic neurotransmission and regulating neuroplasticity, and enhancing antidepressant efficacy through multi-target synergistic effects.

This application discloses antibodies or antigen-binding fragments thereof that specifically bind to estradiol, immune complexes comprising the same, single-chain antibodies that specifically bind to the immune complexes, methods for their preparation, and uses. The antibody or antigen-binding fragment specifically binding to estradiol comprises a first heavy chain variable region and a first light chain variable region; wherein the first heavy chain variable region comprises first heavy chain CDR1, first heavy chain CDR2, and first heavy chain CDR3, and the first light chain variable region comprises first light chain CDR1, first light chain CDR2, and first light chain CDR3, and each of the six CDRs comprises an amino acid fragment with the sequence shown in SEQ ID NO: 1-6. Applying this antibody or antigen-binding fragment specifically binding to estradiol, along with ScFv selected based on it, to the sandwich method for detecting E2 in serum can significantly reduce background signal and improve the signal-to-noise ratio.

The application discloses a preparation method of estradiol-17beta-alkyl acid ester and belongs to the technical field of preparation and processing of steroid hormone drugs. The method uses estradiol as raw material, dissolves the raw material in an organic solvent, adds alkyl acid, and then adds a catalyst and a dehydrating agent to generate a mixture of 3, 17beta-dialkyl acid ester and 17beta-alkyl acid ester, and then adds a hydrolysis reagent to generate 17beta-alkyl acid ester. The method uses a new dehydrating agent and a specific catalyst to solve the problems of high temperature, low yield, expensive and toxic reagents in the estradiol 17beta-hydroxyl esterification process of the traditional process, and the process conditions are more moderate, the purity and yield of the prepared product are higher, the reagents are more green and environmentally friendly, and the method is more in line with the industrial development trend of green chemistry.

The application discloses an application of a nuclear receptor target gene in preparation of a biological preparation for blocking activation of diapause larvae, and relates to the field of biotechnology and parasite prevention and control. According to two nuclear receptor targets of Haemonchus contortus HCON_00101910 (regulating activity of worms) and HCON_00023750 (regulating development of larvae), the two nuclear receptor targets are combined with host progesterone and estradiol and are activated, constitute a key signal path in the spring activation process of diapause larvae, and have no homologous genes in mammals, and the safety is excellent. By constructing specific shRNA lentivirus vectors (the silencing efficiency is all greater than or equal to 60%) targeting the two genes, single target or double target synergistic intervention is realized, and the activity-development double key links of worms in the host body can be specifically blocked. The application provides a new paradigm of preventive prevention and control with high specificity and green safety, and provides core technical support for solving the seasonal epidemic problem of blood fluke disease.

The present invention provides a new NK cell culture medium, which belongs to the field of cell culture technology. It includes basal culture medium, serum, cytokines, antibiotics and auxiliary factors, wherein the basal culture medium is selected from RPMI-1640, DMEM or IMDM, the serum is fetal bovine serum or human serum, the cytokines include IL-2, IL-7, IL-15, IL-3, VEGF, GDNF, and the antibiotics are penicillin or streptomycin. The present invention introduces auxiliary factors containing paclitaxel, cocin, ethanolamine, hyaluronic acid, sodium selenite, L-ascorbic acid, pyrroloquinoline quinone, dihydroxypropylphylline, reduced glutathione, madecassoside, D-pantothenate calcium, and estradiol into the basal culture medium, which can significantly increase the proliferation multiples and cell viability of NK cells, and at the same time, promote the expression of CD56 and CD16 by progeny NK cells. Experimental results show that after a 16-day culture period, the present invention causes NK cells to proliferate 377.6 times, the cell viability reaches 98.2%, and the expression of CD16 + CD56 + The percentage of cell number reached 83.28%.

The application provides a single-chain antibody for sandwich detection of estradiol and a complex antibody thereof and application thereof, wherein the sequence of the single-chain antibody for sandwich detection of estradiol is shown in SEQ.ID No.1; the sequences of CDR1, CDR2 and CDR3 of the heavy chain variable region of the complex antibody for sandwich detection of estradiol are shown in SEQ.ID No.2, SEQ.ID No.3 and SEQ.ID No.4 respectively; and the sequences of CDR1, CDR2 and CDR3 of the light chain variable region are shown in SEQ.ID No.5, SEQ.ID No.6 and SEQ.ID No.7 respectively. The single-chain antibody of the application can specifically combine with small molecule estradiol to form an immune complex, the complex antibody of the application can specifically combine with the immune complex, and the single-chain antibody and the small molecule estradiol are not recognized, and can be applied to complex antibody sandwich method for detection of estradiol, and the sensitivity and accuracy of detection of small molecule estradiol are greatly improved.

The invention discloses a combined package of an estradiol tablet and an estradiol didrogesterone tablet and a preparation method of the combined package. The package is composed of an estradiol tablet and an estradiol didrogesterone tablet. The combined package of the estradiol tablets and the estradiol digestrol tablets comprises the estradiol tablets and the estradiol digestrol tablets which are equal in tablet number, each of the estradiol tablets and the estradiol digestrol tablets comprises a tablet core and a coating layer, the tablet cores are prepared by a high-speed shearing granulation and tabletting process, and the prepared tablets are consistent with an originally developed agent Femoston in in-vitro release behavior, and have the advantages that the estradiol tablets and the estradiol digestrol tablets are combined, so that the estradiol and the estradiol digestrol tablets can be used for preparing the estradiol digestrol tablets; and in-vivo bioequivalence can be achieved. The high-speed shearing granulation mode is used for improving the particle mixing uniformity, so that the medicine content is more uniform, the in-vitro dissolution is stable, and the inter-batch difference is reduced. According to the invention, estradiol with a particle size of less than 20 [mu] m and didrogesterone with a particle size of less than 30 [mu] m are selected, high-speed shearing granulation is carried out by using a high stirring frequency, a special water adding device with a specific opening angle is selected, and the water adding amount, the water adding time and the stirring frequency are controlled at the same time, so that the tablets with rapid dissolution, uniform content and stable quality can be obtained.

The invention provides a traditional Chinese medicine composition for preventing hair loss and promoting hair growth and application thereof, and relates to the technical field of hair loss prevention and promoting hair growth, the traditional Chinese medicine composition is composed of Chinese doughnut, cockscomb, albizia flower, Chinese honey locust, schizonepeta, lithospermum, polygonum multiflorum, prepared rehmannia root, notopterygium root, radix angelicae pubescentis, ruddle and periostracum cicada; in-vitro experiments show that the traditional Chinese medicine composition can promote proliferation of human dermal papilla cells HDPC, relieve the damage degree of HDPC and induce cycle transformation of hair follicles, so that the effect of promoting hair growth is achieved; animal experiments show that the traditional Chinese medicine composition can significantly increase the number of hair follicles and the thickness of skin and dermis fat of mice, reduce the levels of mouse serum IL-2, TNF-alpha and TGF-beta1 and reduce the levels of testosterone, dihydrotestosterone and estradiol in mouse skin tissue, so that hair follicle fibrosis is inhibited, the growth period of hair follicles is accelerated, the growth period is prolonged, the hair loss phenomenon is improved, and the hair loss rate is increased. The hair growth is promoted.

The invention discloses a method for promoting in-vitro maturation of sheep oocytes. The composition comprises an induction culture solution A and an induction culture solution B. The induction culture solution A and the induction culture solution B comprise a basic culture solution, and the induction culture solution A further comprises AMH; the induction culture solution B also contains FSH; the basic culture solution comprises an M199 basic culture medium, oestrus sheep serum, sodium pyruvate, luteinizing hormone, estradiol and a penicillin and streptomycin mixed solution. According to the composition and the method, through the synergistic effect of FSH treatment and AMH treatment, the maturation rate, the activity and the development potential of sheep oocytes are remarkably improved, so that the success rate of in-vitro fertilization and embryo transplantation is improved, an important scientific basis is provided for sheep reproduction and assisted reproduction technologies, related technologies are further optimized, and the application prospect is wide. The reproduction success rate is improved.

The invention provides a product related to non-obstructive azoospermia microscopic sperm extraction, application and a method. The invention discloses application of a reagent for detecting clinical information in preparation of a non-obstructive azoospermia microscopic sperm extraction product. The clinical information comprises age, testis size, testosterone, estradiol E2, androgen T, follicle stimulating hormone FSH, statin B and seminal plasma cell-free DNA motif diversity score. The prediction method comprises the following steps: acquiring clinical information of a to-be-tested object; inputting the clinical information into a prediction model based on machine learning to obtain a probability P of successful microscopic sperm extraction; and according to comparison between the probability P and a reference value, diagnosing or predicting whether the to-be-detected object is suitable for microscopic sperm collection. The prediction method provided by the invention can be used for improving the accuracy of predicting the success rate of microscopic sperm extraction of non-obstructive azoospermia, and has a relatively good clinical application value.